Overview

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

Status:
Completed
Trial end date:
2020-11-05
Target enrollment:
Participant gender:
Summary
A multi-center, open-label study to evaluate the treatment of one oral dose of 2g Solosec™ (Secnidazole) in adolescent girls with BV
Phase:
Phase 4
Details
Lead Sponsor:
Lupin Research Inc
Treatments:
Metronidazole
Secnidazole